Biosimilars Market Access in Psoriasis 2017: TNF-alpha inhibitors Enbrel, Humira, and Remicade have Long Held Dominant Positions in the Market

Dublin, May 30, 2017 -- Research and Markets has announced the addition of the "Biosimilars Market Access in Psoriasis" report to their offering.

Tumor necrosis factor (TNF)-alpha inhibitors Enbrel, Humira, and Remicade have long held dominant positions in the psoriasis market; however, these market leaders face patent expirations and consequent biosimilar launches.

Payers are eager to leverage these changes in the competitive landscape and enact pro-biosimilar access measures, resulting in downward pricing pressures and/or continuing market erosion for first-generation TNF-alpha inhibitors. This rate of erosion may initially be gradual, as neither physicians nor payers are likely to advocate patient switching.

Key Topics Covered:

1. Executive Summary

• US
• Insights and strategic recommendations
• Inflectra carries biosimilar labeling designation, but is not interchangeable
• Physicians hesitant to use biosimilars, but understand that payers may hold sway

2. Five Major EU Markets

• Insights and strategic recommendations
• Uptake of biosimilar TNF-alpha inhibitors varies across EU markets as the EMA does not determine interchangeability
• Most physicians and payers consider biosimilars to be interchangeable, and an opportunity to reduce costs, but worries around indication extrapolation remain
• Payers use biosimilars to pressure originators on pricing
• Hospitals continue to procure both biosimilars and originators; dynamic pricing environment observed
• Biosimilars will be used as price benchmarks for pipeline agents
• Payers are unlikely to implement strong incentives to drive uptake of biosimilar infliximab due to limited use of the drug
• Bibliography

3. Methodology

For more information about this report visit http://www.researchandmarkets.com/research/7tcv43/biosimilars

CONTACT: Research and Markets
         Laura Wood, Senior Manager
         [email protected]
         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900
         U.S. Fax: 646-607-1907
         Fax (outside U.S.): +353-1-481-1716
         Related Topics: Biosimilars and Biosuperiors, Psoriasis Drugs